Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm and semiconductor stocks. However, market leadership was uneven, mirroring the Tech Bubble: high-beta stocks outperformed while high-quality companies lagged, affecting Conestoga’s quality-focused strategies. Management expressed confidence in long-term outcomes, noting that speculative leadership won’t last as monetary policy tightens and market breadth improves. The firm remains committed to high-quality growth businesses, expecting these to regain favor as leadership broadens. The Conestoga Micro-Cap Composite achieved a solid second quarter with a 22.16% net return, although it underperformed the Russell Microcap Growth Index’s 28.98% return. During this period, Micro-Cap Growth surpassed all major equity benchmarks, which reflects improved investor sentiment towards smaller-cap stocks, but the gains were primarily driven by a limited set of high-beta, high-momentum stocks. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Conestoga Capital Advisors highlighted Twist Bioscience Corporation (NASDAQ:TWST) as a notable contributor. Twist Bioscience Corporation (NASDAQ:TWST) is a leading biotechnology company specializing in the manufacture and sale of synthetic DNA-based products. On August 06, 2026, Twist Bioscience Corporation (NASDAQ:TWST) closed at $109.08 per share. The one-month return of Twist Bioscience Corporation (NASDAQ:TWST) was 20.35%, and its shares gained 325.43% over the past 52 weeks. Twist Bioscience Corporation (NASDAQ:TWST) has a market capitalization of $6.84 billion.
Conestoga Capital Advisors stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its Q2 2026 investor letter:
“Twist Bioscience Corporation (NASDAQ:TWST) develops synthetic DNA products and genomic tools for life sciences research and drug discovery. The company delivered another strong quarter, driven by accelerating demand for its DNA synthesis platform and growing adoption in AI-enabled drug discovery. Revenue increased 19% year-over-year, reinforcing confidence that TWST’s technology leadership and expanding product portfolio continue to drive market share gains.”
Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 30 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the first quarter, up from 24 in the previous quarter. In the second quarter of fiscal 2026, Twist Bioscience Corporation’s (NASDAQ:TWST) total revenue rose to $110.7 million, reflecting a year-over-year increase of over 19%. While we acknowledge the risk and potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Twist Bioscience Corporation (NASDAQ:TWST) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Twist Bioscience Corporation (NASDAQ:TWST) and shared Artisan Small Cap Fund’s insight on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
